University of Turin

About: University of Turin is a education organization based out in Turin, Piemonte, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 29607 authors who have published 77952 publications receiving 2480900 citations. The organization is also known as: Universita degli Studi di Torino & Università degli Studi di Torino.

UVCS/SOHO Empirical Determinations of Anisotropic Velocity Distributions in the Solar Corona

Abstract: We present a self-consistent empirical model for several plasma parameters of a polar coronal hole near solar minimum, derived from observations with the Solar and Heliospheric Observatory Ultraviolet Coronagraph Spectrometer. The model describes the radial distribution of density for electrons, H0, and O5 + and the outflow velocity and unresolved most probable velocities for H0 and O5 + during the period between 1996 November and 1997 April. In this Letter, we compare observations of H I Lyα and O VI λλ1032, 1037 emission lines with spatial models of the plasma parameters, and we iterate for optimal consistency between measured and synthesized observable quantities. The unexpectedly large line widths of H0 atoms and O5 + ions at most radii are the result of anisotropic velocity distributions, which are not consistent with purely thermal motions or the expected motions from a combination of thermal and transverse wave velocities. Above 2 R, the observed transverse, most probable speeds for O5 + are significantly larger than the corresponding motions for H0, and the outflow velocities of O5 + are also significantly larger than the corresponding velocities of H0. We discuss the constraints and implications on various theoretical models of coronal heating and acceleration.

AME Position Statement on adrenal incidentaloma

Abstract: Objective: To assess currently available evidence on adrenal incidentaloma and provide recommendations for clinical practice. Design: A panel of experts (appointed by the Italian Association of Clinical Endocrinologists (AME)) appraised the methodological quality of the relevant studies, summarized their results, and discussed the evidence reports to find consensus. Radiological assessment: Unenhanced computed tomography (CT) is recommended as the initial test with the use of an attenuation value of %10 Hounsfield units (HU) to differentiate between adenomas and non-adenomas. For tumors with a higher baseline attenuation value, we suggest considering delayed contrast-enhanced CT studies. Positron emission tomography (PET) or PET/CT should be considered when CT is inconclusive, whereas fine needle aspiration biopsy may be used only in selected cases suspicious of metastases (after biochemical exclusion of pheochromocytoma). Hormonal assessment: Pheochromocytoma and excessive overt cortisol should be ruled out in all patients, whereas primary aldosteronism has to be considered in hypertensive and/or hypokalemic patients. The 1 mg overnight dexamethasone suppression test is the test recommended for screening of subclinical Cushing’s syndrome (SCS) with a threshold at 138 nmol/l for considering this condition. A value of 50 nmol/l virtually excludes SCS with an area of uncertainty between 50 and 138 nmol/l. Management: Surgery is recommended for masses with suspicious radiological aspects and masses causing overt catecholamine or steroid excess. Data are insufficient to make firm recommendations for or against surgery in patients with SCS. However, adrenalectomy may be considered when an adequate medical therapy does not reach the treatment goals of associated diseases potentially linked to hypercortisolism.

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

Abstract: Purpose This phase III, multicenter, randomized, placebo-controlled trial assessed the efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin and paclitaxel in chemotherapy-naive patients with unresectable stage IIIB or IV non–small-cell lung cancer (NSCLC). Patients and Methods Nine hundred twenty-six patients were randomly assigned to receive up to six 21-day cycles of carboplatin area under the curve 6 and paclitaxel 200 mg/m2 (CP) on day 1, followed by either sorafenib 400 mg twice a day (n = 464, arm A) or placebo (n = 462, arm B) on days 2 to 19. The maintenance phase after CP consisted of sorafenib 400 mg or placebo twice a day. The primary end point was overall survival (OS); secondary end points included progression-free survival and tumor response. Results Overall demographics were balanced between arms; 223 patients (24%) had squamous cell histology. On the basis of a planned interim analysis, median OS was 10.7 months in arm A and 10.6 months in arm B ...